Key result
Endothelin-1 inhibits cardiac norepinephrine re-uptake via the endothelin A receptor and attenuates exocytotic norepinephrine release via the endothelin B receptor in male rat hearts.
Why the study?
Does Endothelin-1 inhibit the neuronal norepinephrine transporter in rat hearts?
Does Endothelin-1 inhibit the neuronal norepinephrine transporter in rat hearts?
Endothelin-1 impairs cardiac norepinephrine re-uptake via ET(A) receptors, promoting sympathetic overstimulation in failing hearts, which can be mitigated by ET(A) antagonism.
Answers are grounded in this paper and cite their sources.
Findings in rat hearts remain hypothesis-generating; leaves open ET(A) antagonism effects on norepinephrine uptake in human heart failure.
OBJECTIVE: Endothelin-1 (ET-1) potentiates norepinephrine (NE)-induced contractile responses. An impairment of cardiac NE re-uptake by the neuronal NE transporter (NET) contributes to an increased NE net release in failing hearts. We hypothesized that both phenomena are caused by ET-1-mediated inhibition of NET. METHODS: [3H]-NE-uptake, electrical field stimulation-evoked NE overflow and left ventricular contractility (LV-dp/dt(max)) were measured in isolated perfused rat hearts. NET density on cardiac plasma membranes was determined by [3H]-mazindol binding. Experimental heart failure in rats was induced by transverse aortic constriction (TAC). RESULTS: ET-1 inhibited cardiac [3H]-NE-uptake in a concentration- and time-dependent manner. The endothelin A receptor (ET(A)) antagonist BQ123 but not the endothelin B receptor (ET(B)) antagonist BQ788 abolished ET-1-induced reduction of [3H]-NE-uptake. Likewise, ET-1, but not the ET(B) agonist sarafotoxin S6c, enhanced the stimulated overflow of endogenous NE. In contrast, ET-1 inhibited the stimulated NE overflow during NET blockade (exocytotic NE release) via activation of ET(B). In isovolumically contracting healthy hearts, ET-1 potentiated the NE- but not isoprenaline-induced increase in LV-dp/dt(max). Since isoprenaline is not a NET substrate, the enhanced LV-dp/dt(max) response to NE thus depends on NET. In TAC rats, ET(A) antagonism by darusentan improved both impairment of cardiac [3H]-NE-uptake and reduction of [3H]-mazindol binding sites. CONCLUSION: ET-1 inhibits cardiac NE re-uptake via ET(A) but attenuates exocytotic NE release via ET(B), resulting in opposite effects on cardiac NE net release. In healthy hearts, ET(A)-mediated inhibition of NE re-uptake exceeds ET(B)-mediated silencing of NE release and potentiates the NE-induced increase in left ventricular contractility. In TAC rats, endogenous ET-1 impairs NE re-uptake and promotes sympathetic overstimulation of failing hearts.
No takes yet. Share an insight, caveat, or question.
Backs et al. (2005) studied Experimental heart failure. Endothelin-1 was evaluated on Cardiac [3H]-norepinephrine uptake, stimulated norepinephrine overflow, and left ventricular contractility. Endothelin-1 inhibits cardiac norepinephrine re-uptake via the endothelin A receptor and attenuates exocytotic norepinephrine release via the endothelin B receptor in male rat hearts.
Synapse has enriched 10 related papers. Consider them for comparative context: